Right now: All sources checked on schedule. Last full check Oct 29, 2026, 00:17 UTC.
Sources
| Source | What we use it for | How we read it | Excerpts | Status | Last checked |
|---|---|---|---|---|---|
| U.S. Securities and Exchange Commission (EDGAR) | regulatory filing | EDGAR submissions API (data.sec.gov/submissions/CIK##########.json) for Form 8-K, 8-K/A, 6-K and Form D/D-A; 8-K primary document and EX-99.1 press release fetched as HTML and normalised to plain text; Form D structured XML (primary_doc.xml) rendered as a fixed-format record; every 6h, ≤5 req/s, declared User-Agent with contact address, backoff on 403/429 | Short attributed excerpts + link to the filing | On schedule | Oct 29, 2026, 00:17 UTC |
| U.S. Department of the Treasury, Bureau of the Fiscal Service (USAspending.gov) | government award | USAspending API v2 search/spending_by_award (contracts A-D and grants 02-05) by recipient name; only exact recipient-name matches kept; each award stored as a fixed-format text record; every 6h, ≤5 req/s | Award fields quoted verbatim + link to the award page; obligated amounts labelled as obligations, not revenue | On schedule | Oct 29, 2026, 00:17 UTC |
Companies
| Company | Listing | What we follow | Developments | Latest |
|---|---|---|---|---|
| BrainsWay | Nasdaq BWAY | SEC filings (8-K) and US federal awards | 13 | Oct 26, 2026 |
| Longeveron | Nasdaq LGVN | SEC filings (8-K) and US federal awards | 13 | Oct 26, 2026 |
| Lifeward | Nasdaq LFWD | SEC filings (8-K) and US federal awards | 12 | Oct 27, 2026 |
| Myomo | NYSE MYO | SEC filings (8-K) and US federal awards | 12 | Oct 5, 2026 |
| Nexalin Technology | Nasdaq NXL | SEC filings (8-K) and US federal awards | 11 | Sep 28, 2026 |
| electroCore | Nasdaq ECOR | SEC filings (8-K) and US federal awards | 7 | Sep 8, 2026 |
| Humacyte | Nasdaq HUMA | SEC filings (8-K) and US federal awards | 7 | Sep 22, 2026 |
| Neuronetics | Nasdaq STIM | SEC filings (8-K) and US federal awards | 7 | Aug 11, 2026 |
| Twist Bioscience | Nasdaq TWST | SEC filings (8-K) and US federal awards | 7 | Aug 4, 2026 |
| Intellia Therapeutics | Nasdaq NTLA | SEC filings (8-K) and US federal awards | 6 | Sep 8, 2026 |
| ClearPoint Neuro | Nasdaq CLPT | SEC filings (8-K) and US federal awards | 5 | Oct 28, 2026 |
| Ginkgo Bioworks | NYSE DNA | SEC filings (8-K) and US federal awards | 5 | Aug 5, 2026 |
| NeuroOne Medical | Nasdaq NMTC | SEC filings (8-K) and US federal awards | 5 | Oct 5, 2026 |
| NeuroPace | Nasdaq NPCE | SEC filings (8-K) and US federal awards | 5 | Aug 11, 2026 |
| Vivani Medical | Nasdaq VANI | SEC filings (8-K) and US federal awards | 5 | Aug 13, 2026 |
| Dexcom | Nasdaq DXCM | SEC filings (8-K) and US federal awards | 4 | Sep 10, 2026 |
| Beam Therapeutics | Nasdaq BEAM | SEC filings (8-K) and US federal awards | 3 | Aug 4, 2026 |
| BioAge Labs | Nasdaq BIOA | SEC filings (8-K) and US federal awards | 3 | Aug 5, 2026 |
| CRISPR Therapeutics | Nasdaq CRSP | SEC filings (8-K) and US federal awards | 3 | Oct 19, 2026 |
| Lineage Cell Therapeutics | NYSE LCTX | SEC filings (8-K) and US federal awards | 3 | Aug 6, 2026 |
| Prime Medicine | Nasdaq PRME | SEC filings (8-K) and US federal awards | 3 | Aug 6, 2026 |
| Sana Biotechnology | Nasdaq SANA | SEC filings (8-K) and US federal awards | 3 | Aug 10, 2026 |
| Cambrian Bio | Private | SEC filings (8-K) and US federal awards | 1 | Jul 15, 2026 |
| Life Biosciences | Private | SEC filings (8-K) and US federal awards | 1 | Apr 24, 2026 |
| Neuralink | Private | SEC filings (8-K) and US federal awards | 1 | Jun 12, 2025 |
| NewLimit | Private | SEC filings (8-K) and US federal awards | 1 | May 15, 2025 |
| Precision Neuroscience | Private | SEC filings (8-K) and US federal awards | 1 | Sep 28, 2026 |
| Rejuvenate Bio | Private | SEC filings (8-K) and US federal awards | 1 | Jun 18, 2026 |
| Science Corp. | Private | SEC filings (8-K) and US federal awards | 1 | Mar 6, 2026 |
| Colossal Biosciences | Private | SEC filings (8-K) and US federal awards | 0 | Date not stated |
| Loyal (Cellular Longevity) | Private | SEC filings (8-K) and US federal awards | 0 | Date not stated |
| Paradromics | Private | SEC filings (8-K) and US federal awards | 0 | Date not stated |
| Synchron | Private | SEC filings (8-K) and US federal awards | 0 | Date not stated |
Not covered (yet)
Non-US registries, patents, academic papers, conference talks, private funding rounds that aren’t filed with the SEC, and companies whose frontier work is a small part of a larger business. If we add any of these, they’ll appear here first.
Ask for a company
We add a company when its records can be followed reliably and its work sits squarely at the frontier of human enhancement: longevity, neurotechnology, gene and cell engineering, synthetic biology, augmentation or biomonitoring.
Request coverage